A175 REAL-WORLD EXPERIENCE ON SWITCHING FROM ADALIMUMAB TO BIOSIMILARS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE – AN OBSERVATIONAL STUDY FROM THREE TERTIARY CARE CENTRES

BACKGROUND: Inflammatory Bowel Disease (IBD) is a chronic inflammatory condition of the bowel which includes ulcerative colitis (UC), Crohn’s disease (CD) or unspecific IBD (IBDu). Adalimumab (ADA), a humanized monoclonal IgG antibody against tumour necrosis factor-alpha (TNFa), is an effective trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Bedi, H, Rosenfeld, D, Hoang, T, Reise-Filteau, M, Bressler, B, Leung, Y, Singh, S, Rosenfeld, G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Poster Presentations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9991257/
http://dx.doi.org/10.1093/jcag/gwac036.175

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9991257/
http://dx.doi.org/10.1093/jcag/gwac036.175

Ejemplares similares